As of the latest Form 4 filed Jun 18, 2026.
What Ligand Pharmaceuticals Incorporated insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 81 most recent filings for LGND.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-18 | 2026-06-16 | Sabba Stephen L Director | SSale | −2.15K | $254.00 | $545K | No | Form 4 ↗ |
| 2026-06-18 | 2026-06-16 | Sabba Stephen L, Director | MExercise | +2.15K | $66.13 | $142K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Haas Jason Director | SSale | −3.46K | $256.08 | $886K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Haas Jason, Director | SSale | −3.00K | $255.01 | $765K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Haas Jason, Director | MExercise | +1.00K | $51.56 | $51.6K | No | Form 4 ↗ |
| 2026-06-15 | 2026-06-12 | Haas Jason, Director | MExercise | +3.00K | $51.56 | $155K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-11 | Aryeh Jason Director | SSale | −4.50K | $250.00 | $1.13M | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Aryeh Jason, Director | SSale | −500.00 | $250.00 | $125K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | LAMATTINA JOHN L Director | SSale | −3.40K | $251.62 | $857K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | LAMATTINA JOHN L, Director | SSale | −697.00 | $249.53 | $174K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | LAMATTINA JOHN L, Director | SSale | −232.00 | $248.11 | $57.6K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | LAMATTINA JOHN L, Director | SSale | −257.00 | $247.22 | $63.5K | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-05 | Aryeh Jason Director | AAward | +836.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Zimmermann Martine Director | FTax | −182.00 | $237.00 | $43.1K | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Zimmermann Martine, Director | AAward | +836.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Sabba Stephen L Director | AAward | +836.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | LAMATTINA JOHN L Director | AAward | +836.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | KOZARICH JOHN W Director | AAward | +836.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Haas Jason Director | AAward | +836.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-09 | 2026-06-05 | Gray Nancy Ryan Director | AAward | +836.00 | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Reardon Andrew CLO & Secretary | SSale | −200.00 | $230.41 | $46.1K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Reardon Andrew, CLO & Secretary | SSale | −1.22K | $229.47 | $279K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Reardon Andrew, CLO & Secretary | SSale | −584.00 | $228.57 | $133K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Reardon Andrew, CLO & Secretary | SSale | −400.00 | $226.78 | $90.7K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Reardon Andrew, CLO & Secretary | SSale | −1.43K | $225.97 | $324K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Reardon Andrew, CLO & Secretary | SSale | −677.00 | $225.20 | $152K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Reardon Andrew, CLO & Secretary | SSale | −491.00 | $223.95 | $110K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-01 | Reardon Andrew, CLO & Secretary | MExercise | +5.00K | $52.27 | $261K | Yes (planned) | Form 4 ↗ |
| 2026-05-28 | 2026-05-27 | Espinoza Octavio Chief Financial Officer | MExercise | +972.00 | $52.84 | $51.4K | No | Form 4 ↗ |
| 2026-05-28 | 2026-05-27 | Espinoza Octavio, Chief Financial Officer | MExercise | +764.00 | $63.62 | $48.6K | No | Form 4 ↗ |
| 2026-05-14 | 2026-05-13 | KOZARICH JOHN W Director | SSale | −1.57K | $223.50 | $352K | Yes (planned) | Form 4 ↗ |
| 2026-05-14 | 2026-05-13 | KOZARICH JOHN W, Director | MExercise | +1.57K | $69.51 | $109K | Yes (planned) | Form 4 ↗ |
| 2026-05-14 | 2026-05-12 | KOZARICH JOHN W, Director | SSale | −459.00 | $224.00 | $103K | Yes (planned) | Form 4 ↗ |
| 2026-05-14 | 2026-05-12 | KOZARICH JOHN W, Director | MExercise | +459.00 | $69.51 | $31.9K | Yes (planned) | Form 4 ↗ |
| 2026-05-14 | 2026-05-01 | KOZARICH JOHN W, Director | SSale | −116.00 | $234.09 | $27.2K | Yes (planned) | Form 4 ↗ |
| 2026-05-14 | 2026-05-01 | KOZARICH JOHN W, Director | SSale | −105.00 | $232.57 | $24.4K | Yes (planned) | Form 4 ↗ |
| 2026-05-14 | 2026-05-01 | KOZARICH JOHN W, Director | SSale | −165.00 | $231.87 | $38.3K | Yes (planned) | Form 4 ↗ |
| 2026-05-14 | 2026-05-01 | KOZARICH JOHN W, Director | SSale | −1.00 | $229.87 | $229.87 | Yes (planned) | Form 4 ↗ |
| 2026-05-14 | 2026-05-01 | KOZARICH JOHN W, Director | SSale | −80.00 | $227.37 | $18.2K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Reardon Andrew CLO & Secretary | SSale | −800.00 | $234.02 | $187K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Reardon Andrew, CLO & Secretary | SSale | −1.42K | $232.92 | $331K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Reardon Andrew, CLO & Secretary | SSale | −780.00 | $232.04 | $181K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Reardon Andrew, CLO & Secretary | SSale | −370.00 | $230.87 | $85.4K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Reardon Andrew, CLO & Secretary | SSale | −98.00 | $229.71 | $22.5K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Reardon Andrew, CLO & Secretary | SSale | −932.00 | $228.75 | $213K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Reardon Andrew, CLO & Secretary | SSale | −600.00 | $227.45 | $136K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-01 | Reardon Andrew, CLO & Secretary | MExercise | +5.00K | $52.27 | $261K | Yes (planned) | Form 4 ↗ |
| 2026-03-31 | 2026-03-06 | LAMATTINA JOHN L Director | SSale | −2.16K | $200.76 | $434K | No | Form 4 ↗ |
| 2026-03-31 | 2026-03-06 | LAMATTINA JOHN L, Director | MExercise | +2.16K | $114.15 | $247K | No | Form 4 ↗ |
| 2026-03-27 | 2026-03-02 | Espinoza Octavio Chief Financial Officer | AAward | +4.93K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-27 | 2026-03-02 | Davis Todd C Chief Executive Officer | AAward | +10.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-27 | 2026-03-02 | Reardon Andrew CLO & Secretary | AAward | +4.51K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-25 | 2026-03-23 | Sabba Stephen L Director | SSale | −1.00K | $207.87 | $208K | No | Form 4 ↗ |
| 2026-03-13 | 2026-03-11 | Espinoza Octavio Chief Financial Officer | SSale | −3.06K | $225.00 | $688K | Yes (planned) | Form 4 ↗ |
| 2026-03-13 | 2026-03-11 | Espinoza Octavio, Chief Financial Officer | MExercise | +2.40K | $92.65 | $223K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew CLO & Secretary | SSale | −1.14K | $208.87 | $239K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | SSale | −1.45K | $208.12 | $301K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | SSale | −612.00 | $207.01 | $127K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | SSale | −340.00 | $206.37 | $70.2K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | SSale | −460.00 | $205.18 | $94.4K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | SSale | −200.00 | $204.17 | $40.8K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | SSale | −300.00 | $201.70 | $60.5K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | SSale | −93.00 | $200.62 | $18.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | SSale | −207.00 | $199.96 | $41.4K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | SSale | −100.00 | $199.01 | $19.9K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | SSale | −100.00 | $197.70 | $19.8K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Reardon Andrew, CLO & Secretary | MExercise | +5.00K | $52.27 | $261K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio Chief Financial Officer | SSale | −3.41K | $208.80 | $713K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | SSale | −2.46K | $207.91 | $511K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | SSale | −1.59K | $206.89 | $329K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | SSale | −1.46K | $205.79 | $300K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | SSale | −743.00 | $204.74 | $152K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | SSale | −668.00 | $203.63 | $136K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | SSale | −697.00 | $202.79 | $141K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | SSale | −950.00 | $201.73 | $192K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | SSale | −698.00 | $201.09 | $140K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | SSale | −53.00 | $200.08 | $10.6K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | SSale | −699.00 | $198.71 | $139K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | MExercise | +466.00 | $80.72 | $37.6K | Yes (planned) | Form 4 ↗ |
| 2026-03-06 | 2026-03-04 | Espinoza Octavio, Chief Financial Officer | MExercise | +1.61K | $58.49 | $94.0K | Yes (planned) | Form 4 ↗ |
| 2024-05-02 | 2024-04-30 | Aryeh Jason Director | MExercise | +2.41K | $52.30 | $126K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also LGND’s full analysis or the market-wide insider trading feed. The tabs above jump to LGND’s other SEC data.
Source: SEC Form 4 filings for LGND, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.